Ray is a co-founder of Kimia and serves as Senior Director of Drug Discovery Platform Technology where he leads a diverse team involved in the design and application of high throughput technologies for the innovative ATLAS platform.

‍

Prior to Kimia, Ray was Director of Platform Technology at Carmot Therapeutics, where he played a central role in the development and execution of the Chemotype Evolution drug discovery platform from its early beginnings. His contributions resulted in the discovery of all of Carmot’s clinical-stage molecules as well as partnerships with biotech companies including Genentech and also Amgen’s KRAS G12C-targeting effort which resulted in the first approved KRAS targeting molecule, LUMAKRAS™ (sotorasib).

‍

Previously, Ray has held positions at Sunesis Pharmaceuticals where he was a major contributor to the fragment based tethering drug discovery technology, and also at Sirna Therapeutics/Merck where he developed RNAi-small molecule hybrids to probe biological effects of RNAi from the biochemical scale to intact organisms.

‍

Ray holds a MS in Molecular Biology from the University of Iowa. He has authored more than 20 publications and is an inventor on four patents.

‍